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creativecommons.org/Neurologists, geriatricians, and old-age psychiatrists are involved in key tasks in the diagnostic pro-
cess, frequently referring patients with suspected dementia for neuroimaging.
Methods: The research design was a postal survey of all geriatricians, old-age psychiatrists, and neu-
rologists in the Republic of Ireland (N5 176) as identified by the Irish Medical Directory 2011–2012
and supplementary listings.
Results: Almost 65% of specialists did not have access to 2-[18F]fluoro-2-deoxy-D-glucose positron
emission (FDG-PET) or FDG-PET/computed tomography (CT), and 80.3% did not have access to
perfusion hexamethylpropyleneamine oxime single-photon emission computed tomography
(SPECT) or dopaminergic iodine-123-radiolabeled 2b-carbomethoxy-3b-(4-iodophenyl)-N-
(3-fluoropropyl) nortropane SPECT. Most specialists (88.7%) referred patients with mild cognitive
impairment or suspected dementia for magnetic resonance imaging (MRI), 81.7% referred for CT,
and 26.8% for FDG-PET or FDG-PET/CT. Only 44.6% of respondents were aware of dementia-
specific protocols for referrals for neuroimaging.
Conclusion: Specialist access to imaging modalities other than CT and MRI is restricted. Improved
access may affect patient treatment and care.
 2015 The Alzheimer’s Association. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Dementia; Neuroimaging; Geriatricians; Neurologists; Old-age psychiatrists; Access;MRI; CT; Nuclear medicineimaging1. Introduction
Neuroimaging is increasingly regarded as an essential
part of the investigation of a patient with suspected dementia
[1]. Structural imaging has traditionally been used to
exclude other cerebral pathologies in the assessment of sus-
pected cases of dementia and to reveal findings consistent
with Alzheimer’s disease (AD) [2–4]. Some guidelines
recommend its use in the evaluation of every patient withuthor. Tel.: 1353-1-716-6522; Fax: 1353-1-716-
relia.ciblis@ucd.ie
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he Alzheimer’s Association. Published by Elsevier Inc. T
licenses/by-nc-nd/4.0/).suspected dementia [4]. Magnetic resonance imaging
(MRI) is the preferred modality to assist with early diagnosis
and detect subcortical vascular changes, however, computed
tomography (CT) can also be used [2]. Treatable causes of
dementia account for only a small proportion of all causes
of dementia, however, and AD, vascular dementia (VaD), de-
mentia with Lewy bodies (DLB), and frontotemporal de-
mentia (FTD) are far more common causes [1,5].
With advances in technology, neuroimaging is nowconsid-
ered the most important ancillary investigation in the workup
of dementia regarding differential diagnosis andmanagement
decisions [3,4,6,7]. Nuclear scans can help differentiate AD,his is an open access article under the CC BY-NC-ND license (http://
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National Institute for Health and Clinical Excellence/Social
Care Institute for Excellence (NICE/SCIE) note that imaging
may not always be needed for those presentingwithmoderate
to severe dementia if the diagnosis is clear, and recommend
the use of perfusion hexamethylpropyleneamine oxime
(HMPAO) single-photon emission computed tomography
(SPECT) or 2-[18F]fluoro-2-deoxy-D-glucose positron emis-
sion (FDG-PET) to distinguish between these subtypes if the
diagnosis is in doubt [2]. In suspected cases ofDLB, the use of
dopaminergic iodine-123-radiolabeled 2b-carbomethoxy-
3b-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (FP-CIT)
SPECT is recommended to confirm the diagnosis if it is in
doubt [2].
FDG-PET is reimbursed in the United States for the
distinction between AD and FTD [8,9]. In Ireland, PET
scans are covered by the major private health insurance
providers pending preapproval. FP-CIT (DAT-SPECT) is
beneficial in the differentiation of DLB from AD and normal
ageing [10]. Although SPECT and PET are not recommen-
ded for use as the only imaging measures, these modalities
complement structural imaging where diagnostic uncer-
tainty remains [4,11].
InAD, themost common formof dementiawhich accounts
for approximately 60% to 70% of cases [12], atrophy in the
medial temporal lobe, including the hippocampus, is an early
and specific marker of the disease. Structural MRI imaging
can determine volume loss in this region [1,13], and has
been postulated as a marker for the progression of the
disease [14,15]. The appearance of neuritic plaques is one of
the neuropathological hallmarks of AD, the main constituent
of which is the amyloid b protein. This protein is considered
intrinsic to the pathogenetic process of AD and can be
imaged in vivo using PET scans [16]. This allows for an early
detection of the disease. Changes in brainmetabolism can pre-
cede structural brain changes, and temporal, parietal, and pos-
terior singular hypometabolism found inADcan bevisualized
using FDG-PETand help discriminate AD patients from con-
trols [16]. FDG-PET scans showdifferent patterns of hypome-
tabolism in AD and FTD and can therefore assist in the
differential diagnosis of the diseases [8].
At present, most people with dementia do not receive a
formal diagnosis [17]. However, a specific diagnosis can in-
fluence treatment decisions, such as the use of acetylcholin-
esterase inhibitors in AD and DLB, the modification of
vascular risk factors in VaD or carefulness in the use of neu-
roleptics in DLB or FTD [1]. Therefore, it would seem good
patient management would make some imaging support for
the diagnosis indispensable. The European Union (EU) joint
action on Alzheimer’s initiative, Alzheimer’s cooperative
valuation in Europe (ALCOVE) has identified four main
professions as being responsible for most of the dementia
diagnosis pathways: general practitioners, neurologists, ger-
iatricians, and psychiatrists [6]. An exemplary pathway
would have patients first recognized in primary care and
subsequently referred to secondary care services such as amemory clinic or directly to geriatricians, old-age psychia-
trists, or neurologists, and would involve neuroimaging as
an important part of this pathway.
In view of the underdiagnosis of dementia and the signif-
icance of neuroimaging in the diagnostic process, it is crucial
that specialists have timely access to neuroimaging investi-
gations and are confident in selecting the most appropriate
modality. The present study investigated specialists’ per-
spectives on access to neuroimaging investigations for sus-
pected cases of dementia in Ireland and current referral
patterns because adequate access and appropriate use of neu-
roimaging is required if diagnostic rates are to be improved.2. Methods
2.1. Study design and participants
The research used a questionnaire-based study design. A
postal survey questionnaire was addressed to all geriatricians,
old-age psychiatrists, and neurologists in Ireland as identified
through the Irish Medical Directory (IMD) 2011–2012. In
addition, individual old-age psychiatrists, not contained in
the IMD, were identified through a supplementary listing.
A total of 176 individual questionnaires were sent by post
to the identified geriatricians (n5 84), old-age psychiatrists
(n5 46), and neurologists (n5 46). Respondents were given
4 weeks to return the questionnaire. Returned survey sheets
were completely anonymous and there was no follow-up.
2.2. Materials
The questionnaire consisted of five main sections and
included both open and closed questions. Section A ascer-
tained the demographic characteristics of the sample. Sec-
tion B enquired about satisfaction with diagnostic
capabilities within the health service and access to neuroi-
maging. Section C established specialists’ current referral
patterns in neuroimaging in dementia, their reasons for
referral, and their use of protocols. Section D asked about
the usefulness of reports on neuroimaging investigations.
2.3. Statistical analysis
Data analysis was carried out using IBM SPSS Statistics
Version 20. Descriptive statistics are reported for most
variables. Chi-square analysis including standardized resid-
uals was performed to establish associations between cate-
gorical variables. Content analysis was used to examine
open questions.3. Results
3.1. Demographics
A total of 76 questionnaires were returned corresponding
to a response rate of 43.2%. Over half of respondents
(58.3%) were male. Most respondents (42.1%) were geriatri-
cians, 28.9% were old-age psychiatrists and just over quarter
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consultants.
The respondents’ year of qualification ranged from 1972
to 2009 (8%, 1972–1981; 44%, 1982–1991; 41.3%, 1992–
2001; 6.7%, 2002–2009). Neurologists were more likely to
have qualified more recently (2002–2009; c2 5 21.81,
P5.009, standard residual [SR]5 3.4). The average number
of years clinicians had spent in their current jobwas 7.8 years
(standard deviation or SD 5 5.95; range 5 0.5–30 years).
Most participants (77.6%) worked in the public health
service or under the Irish General Medical Scheme (GMS)
which entitles patients with an income below a particular
threshold to receive certain health services, including radi-
ology examinations, free of charge. Another 11.8% worked
in mixed practices, that is, in private practice and under the
GMS. Just 10.5% worked in private practice only. Over half
of respondents (57.4%) worked in county Dublin which is
also a major urban area.
More than half of participants (54.1%) reported that most
patients (75%–100%) were over 65 years of age, and 27%
stated that between half and three quarters of their patients
were of this age group. As expected neurologists were
more likely to see younger patients, with half of them report-
ing that only 25% to 50% of their patients were aged more
than 65 years (c2 5 49.82, P 5 .001, SR 5 3.7). Nearly
all participants (97.4%) were involved in the diagnosis of
mild cognitive impairment (MCI) or dementia.3.2. Diagnostic capabilities within the health service area
Although about half of participants rated the proficiency
in the diagnosis of MCI or dementia within their Health Ser-
vice Executive region as excellent (4.1%) or good (46.6%),
nearly 50% of respondents rated it as fair (39.7%) or poor
(9.6%). There was no significant association between the
geographic location that participants worked in and the rat-
ing of the capabilities (c2 5 7.03; P 5 .855) or between
specialization as geriatrician, old-age psychiatrist, or neurol-
ogist and the rating (c2 5 8.71; P 5 .191).
Suggestions to improve the rate of diagnosis included, in
order of frequency: better access to neuropsychology
(n 5 23), improved access to neuroimaging (n 5 18), and
better access to memory clinics (n 5 16). A higher percent-
age of geriatricians (40.6%) cited better access to neuropsy-
chology compared with old-age psychiatrists (23.8%) and
neurologists (30%).
Most participants considered neuroimaging in dementia
as important (46.1%) or very important (25%). There
was no association between specialization and the reported
importance of neuroimaging in dementia (c2 5 7.74;
P 5 .560).Fig. 1. Reported availability of neuroimaging modalities.3.3. Access to neuroimaging
All specialists reported that they had access to CT and
MRI was available to most (see Fig. 1), however, nearlytwo thirds of participants (64.5%) did not have access to
FDG-PET or FDG-PET/CT and most respondents (80.3%)
did not have access to HMPAO SPECT or FP-CIT SPECT.
Although there was no significant association between
specialization and reported availability of most neuroimag-
ing modalities, there was a significant link between special-
ization and reported availability of FDG-PET or FDG-PET/
CTwhereby neurologists were more likely to have access to
this modality than geriatricians or old-age psychiatrists
(c2 5 7.94; P 5 .047, SD 5 1.7). There was no significant
association between geographic location and the availability
of the individual neuroimaging modalities.3.4. Current referrals for neuroimaging
Nearly all respondents referred patients with MCI
(90.8%) or suspected dementia (96.1%) for neuroimaging.
MRI and CTwere the most common forms of neuroimaging
at 88.7% and 81.7% (no statistical difference, t 5 21.78;
df5 70; P5 .79). Over a quarter (26.8%) referred these pa-
tients for FDG-PETor FDG-PET/CT. Only 4.2% referred for
HMPAO SPECT and 11.3% for FP-CIT SPECT (Fig. 2).
Although there was no significant association between
clinicians’ specialization and the neuroimaging modalities
they referred to overall, neurologists were more likely to
report that they referred clients to FDG-PET or FDG-PET/
CT (c2 5 9.62; P 5 .008, SR 5 2.2) and less likely to refer
to CT (c2 5 14.77; P 5 .001, SR 5 2.8). There was no sig-
nificant association between specialists’ geographic location
and the imaging modalities they referred to.
A total of 62.5% of respondents who referred patients for
neuroimaging reported that there were modalities that they
would like to have access to but that were unavailable to
them. The modalities most frequently listed as unavailable
were PET (n 5 17), FDG-PET, or FDG-PET/CT (n 5 18)
and SPECT (n5 18). Again there was no significant link be-
tween specialists’ geographic location and the unavailability
of imaging modalities they would like to have access to
(c2 5 20.61; P 5 .545).
Most participants were either somewhat confident
(54.8%) or very confident (32.9%) in selecting the most
appropriate neuroimaging modality. There was no associa-
tion between specialization and reported confidence
Fig. 2. Current referrals for the individual imaging modalities.
Fig. 3. Reported reasons for referral for neuroimaging.
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ported that they were very confident (13.2%) or somewhat
confident (73.7%) in understanding neuroimaging in demen-
tia. Most requests for neuroimaging were either never
(45.9%) or rarely (41.9%) refused, and only 10.8% reported
that they were sometimes refused. Reasons for a refusal
included the inaccessibility of modalities, a lack of resources
and funding, restrictions in health insurance coverage, and a
questioning of the validity of the request by the radiologist.
There was a significant association between neuroimaging
refusal and referral for MRI. Respondents who referred to
MRI were more likely to state that their referrals were quite
frequently refused (c25 8.05; P5 .045, SR5 2.6). This as-
sociation was not evident for the other imaging modalities.
Factors not to request a scan included client characteristics
such as frailty, advanced disease or clear diagnosis, and
cost, a lack of availability of neuroimaging, and waiting
times.
Less than half of respondents (44.6%) were aware of
dementia-specific protocols for referrals for neuroimaging.
There was no association between specialization and aware-
ness of dementia-specific protocols (c25 2.41; P5 .299) or
year of qualification and this awareness (c2 5 2.43;
P 5 .486). However, there was a significant association be-
tween referral of a patient under 65 years of age and aware-
ness of dementia-specific protocols (c2 5 3.75; P 5 .044),
which was not found for other reasons for referral.3.5. Reasons for referral
Specialists’ reported reasons for referral for neuroimag-
ing are displayed in Fig. 3. The question allowed for multiple
responses. Most clinicians referred patients with suspected
MCI or dementia for neuroimaging to rule out other causes
(94.5%). A total of 69.9% referred to establish a differential
diagnosis, and 63% referred to determine a dementia sub-
type. Just under half (46.6%) referred patients with sus-
pected MCI or dementia for neuroimaging because the
patient was under 65 years of age. Only 13.7% referred
based on clinical guidelines such as the NICE/SCIE guide-
lines.There was an association between the rated importance of
neuroimaging and referring patients to establish a differen-
tial diagnosis (c2 5 8.84; P 5 .031) or a dementia subtype
(c2 5 9.77; P 5 .021) but not for any of the other reasons.
No link was found between specialization and the reason
for referral for neuroimaging.3.6. Radiology report
Nearly all clinicians (97.4%) reported that they had ac-
cess to reports on neuroimaging investigations about patients
with suspected MCI or dementia. Most considered the infor-
mation from the radiology report helpful (71.6%) or very
helpful (17.6%) and rated their understanding of the report
as good (71.6%) or excellent (12.2%). Those involved in ex-
plaining the report to patients and their family members
found it easy (72.2%) or very easy (11.1%) to explain the in-
formation. There was no link between specialization and the
reported usefulness of the radiology report (c2 5 6.59;
P5 .680) or the perceived difficulty of explaining the report
to patients (c2 5 7.53; P 5 .821).4. Discussion
Nearly half of respondents rated the proficiency in the
diagnosis of MCI or dementia within their health service re-
gion as fair or poor. A lack of access to neuropsychological
assessments, memory clinics, and neuroimaging investiga-
tions appeared to be key factors. Almost two thirds of partic-
ipants stated that there were neuroimaging modalities that
they would like to access but that were unavailable. These
were mainly nuclear medicine imaging modalities, that is,
PET and SPECT. Although most respondents referred pa-
tient with suspected dementia for neuroimaging to rule out
other causes that are amenable to treatment, for which
MRI or CT investigations are predominantly used [7,9],
only approximately 1% to 10% of these investigations
reveal reversible causes of dementia, and AD, VaD, DLB,
and FTD are far more often the cause [4,5]. The results
have shown that more than two-thirds of specialists referred
suspected dementia cases to establish a differential diagnosis
or a subtype diagnosis for which nuclear medicine investiga-
tions are frequently required. A subtype diagnosis is
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management plan for patients and their families and helps
those affected to know what to expect and which interven-
tions might be beneficial [18]. Yet specialists’ reported ac-
cess to modalities other than CT or MRI was limited.
Nearly two-thirds of respondents reported that they did
not have access to FDG-PETor FDG-PET/CT, and the over-
whelming majority did not have access to HMPAO SPECT
or FP-CIT SPECT in spite of the NICE/SCIE guidelines rec-
ommending the use of HMPAO SPECT, or FDG-PET, to
help differentiate AD, VaD, and FTD [7]. The use of FP-
CIT (DAT-SPECT) is recommended to confirm suspected
cases of DLB [7] because it is beneficial in the differentia-
tion of DLB from AD and normal ageing [4,9]. Although
SPECT and PET are not recommended for use as the only
imaging measure, these modalities complement structural
imaging where diagnostic uncertainty remains and
therefore constitute an important tool [4,11].
The higher percentage of referrals for FDG-PET
compared with SPECT in the current sample may be related
to recommendations such as the American College of Radi-
ology appropriateness criteria for dementia which state that
the differentiation between AD and VaD is better achieved
using PET than SPECT investigations [19,20]. It might
also be due to the higher reported availability of PET.
According to a recent systematic review, PET appears to
be superior to SPECT in identifying dementia subtypes
and progression from MCI to AD although uncertainty
remains in view of a lack of direct comparisons [21].
Almost three times as many specialists reported that they
referred to FP-CIT SPECT compared with HMPAO SPECT
though equal availability was reported. This could indicate
the use of FP-CIT SPECT to aid in the diagnosis of DLB
[10,19,22], because DLB is the second or third most
common form of dementia [21] and HMPAO SPECT does
not sufficiently differentiate between DLB and AD. Neurol-
ogists were found to be more likely to refer to FDG-PET or
FDG-PET/CTand less likely to refer to CT than geriatricians
or old-age psychiatrists. The slightly better reported accessi-
bility to this modality for this group might be a factor and
this could be because neurologists are generally presented
with patients of different age groups and therefore more
likely to require advanced imaging technology to diagnose
various pathologies.
Although access to CT and MRI appeared to be adequate
overall, a total of 4% of specialists did not have access to
MRI in spite of its use being recommended over the use of
CT in early diagnosis and detection of subcortical diagnosis
in UK guidelines [7]. MRI increases specificity, and is prefer-
able to CT for detecting vascular lesions in patients with de-
mentia [4,19]. Moreover, CT has limited utility in the early
detection of AD and in differentiating AD from other
causes of dementia, whereas early changes in AD consistent
with pathology (although not diagnostic in their own right)
have been demonstrated using MRI [23]. Possible causes
for the reduced availability of MRI in spite of its clinical ben-efits include the higher cost associated with MRI in compar-
ison to CT and its reduced insurance coverage, however,
specialists still referred suspected cases of dementia more
frequently to MRI than to CT in concordance with clinical
guidelines. This is in linewith results of the ALCOVE project
which revealed that MRI was the most commonly used mo-
dality of medical imaging for dementia, except in late-stage
dementia [6]. The specialists in this study reported that only
10% of their referrals to neuroimaging were refused. MRI re-
ferrals were found to be declined more frequently when
compared with other modalities. This could be related to is-
sues regarding accessibility and a lack of resources. More-
over, the use of CT might be considered adequate for
certain investigations.Waiting lists which can run fromweeks
to months could also be a contributing factor [24].
The neuroimaging modalities that the specialists reported
they would like to have access to but that were currently un-
available to them suggest that specialists are aware of
advanced imaging modalities to aid in the diagnosis of de-
mentia but are limited in their access. Specialists’ expertise
in the area is also reflected in their high reported confidence
in selecting the appropriate neuroimaging modality and their
high confidence in their understanding of neuroimaging in
dementia.
The radiology report is often the main means of commu-
nication between the radiologist and the referring specialist.
As such it must be easily understood, accurate, timely and
appropriately detailed [25,26]. Its usefulness and current
form have been debated, however. A recent survey of
referring clinicians found that only 44.6% of specialists
agreed that language and style of the radiology report were
mostly clear, and only 41.4% considered the report
important [27]. The use of structured reporting has been sug-
gested but is debated [28]. The specialists in the current
survey considered the radiology report sufficiently clear
and useful. They reported no difficulties in explaining the in-
formation from the report to patients and their family mem-
bers. This could indicate that the radiology report in its
current form is sufficient for specialists to aid in the diag-
nosis of dementia.
In the absence of national clinical guidelines for the diag-
nosis of dementia it is not surprising that very few specialists
reported referring patients with suspected dementia for neu-
roimaging based on guidelines. The creation of national
guidelines has been called for, and the importance of such
guidelines has been emphasized [29]. Likewise awareness
of dementia-specific protocols for referrals for neuroimag-
ing was low and would indicate a requirement for standard-
ized protocols and further training in this area.
A strength of this study is the composition of the sample
which was a good representation of the main specialists
involved in the diagnosis of dementia [6]. The majority
worked in the public health service and were thus represen-
tative of specialists in this area, however, less than half of the
addressed specialists replied to the survey which could have
introduced a bias.
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Neuroimaging is an important tool in the diagnostic
workup of dementia. With advances in imaging technology,
it is no longer merely used to rule out other causes but also to
assist in subtype diagnosis. This generally requires more
advanced imaging modalities. Similar to other countries,
the current research has revealed that access to modalities
other than CT and MRI is limited [24,30]. This lack of
access might impact on patient treatment and care. The
provision of adequate access to neuroimaging is therefore
imperative and an important step toward improving
diagnostic rates.
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1. Systematic review: Literature searches were con-
ducted using PubMed and Google Scholar to identify
articles and guidelines on neuroimaging in dementia
and its use by specialists.
2. Interpretation: Neuroimaging is considered an
important tool in the diagnostic workup of dementia.
Yet many specialists report inadequate access in
particular to nuclear medicine scans which can be
important in establishing a subtype diagnosis. A
lack of access might therefore affect patient treat-
ment and care.
3. Future directions: A comprehensive investigation of
specialists’ access to neuroimaging in dementia in
other countries might further highlight the require-
ment for adequate access to neuroimaging investiga-
tions for suspected dementia patients to facilitate an
accurate diagnosis and ensure appropriate treatment
and care.
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